share_log

HC Wainwright & Co. Maintains Buy on NRX Pharmaceuticals, Adjusts Price Target To $19 (1-10 Reverse Stock Split)

HC Wainwright & Co. Maintains Buy on NRX Pharmaceuticals, Adjusts Price Target To $19 (1-10 Reverse Stock Split)

华盛顿健康咨询公司维持对NRX制药的买入评级,将价格目标调整为19美元(1-10股票拆分)
Benzinga ·  08/05 15:42  · 评级/大行评级

HC Wainwright & Co. analyst Vernon Bernardino maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy, adjusts target to $19 from $2 (1-10 Reverse Stock Split).

HC Wainwright&Co.分析师Vernon Bernardino认为NRX制药(纳斯达克股票代码:NRXP)值得买入,将目标价从2美元(1-10股票回拨拆分)调整至19美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发